摘要
目的观察β受体阻滞剂卡维地洛对慢性充血性心力衰竭(CHF)的临床疗效及安全性。方法将慢性充血性心力衰竭患者120例,随机分为卡维地洛组60例,美托洛尔组60例,随访6个月,比较2组的心功能改善情况。结果卡维地洛组及美托洛尔用药后2组患者左心室舒张末期内径(LVEDd)、左心室收缩期内径(LVEDs)、左心房内径(LAD)显著缩小(均为P<0.01);左心室射血分数(LVEF)显著增加(卡维地洛组P<0.01,美托洛尔组P<0.05),且卡维地洛对LVEDs、RVD、LVEF的改善作用更优于美托洛尔(LVEDs、RVD均为P<0.01,LVEF为P<0.05)。结论卡维地洛及美托洛尔对CHF均有较好疗效,且卡维地洛疗效优于美托洛尔。
Objective To assess the curative effects and safety of preceptor blocking agent Carvedilol on patients with chronic heart failure. Methods 120 cases with chronic congestive heart failure were randomly divided into Carvedilol group （n = 60） and Metoprolol group（ n = 60）. After the treatment of 6 months, the improvement of heart function was compared between the two groups. Results The left ventricular end-diastolic dimension（LVEDd） ,left ventricular end-systolic dimension （LVEDs） and left atrial dimension（LAD） of both groups were decreased significantly（P 〈0.01 ） and left ventrieular ejection fraction（LVEF） of the two groups increased significantly（ Carvedilol group, P 〈 0.01 ;Metoprolol group P 〈 0.05 ） compared to the normal reference value. The effect of Carvedilol was better than Metoprolol （ LVEDs P 〈 0.01 ; LVEF P 〈 0.05 ）. Conclusions Both Carvedilol and Metoprolol can improve the heart function obviously in the patients with CHF, and the effect of Carvedilol is better than Metoprolol.
出处
《中华全科医学》
2008年第10期1038-1039,共2页
Chinese Journal of General Practice
